



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

**Correction to
Lancet Infect Dis 2023;
published online
March 15. [https://doi.org/10.1016/S1473-3099\(23\)00180-9](https://doi.org/10.1016/S1473-3099(23)00180-9)**

Molina KC, Ginde AA. Real-world use of nirmatrelvir-ritonavir: who benefits? *Lancet Infect Dis* 2023; published online March 15. [https://doi.org/10.1016/S1473-3099\(23\)00180-9](https://doi.org/10.1016/S1473-3099(23)00180-9)—In this Comment, Adit A Ginde's affiliation should have been "Department of Emergency Medicine, Colorado University School of Medicine, Aurora, CO, USA". This correction has been made to the online version as of March 29, 2023, and will be made to the printed version.

**Correction to
Lancet Infect Dis 2023;
23: e122–37**

Domínguez J, Boeree MJ, Cambau E, et al. Clinical implications of molecular drug resistance testing for *Mycobacterium tuberculosis*: a 2023 TBnet/RESIST-TB consensus statement. *Lancet Infect Dis* 2023; 23: e122–37—In this Review, in table 2, "rrs full gene" should have been added for Amikacin and Deeplex Myc-TB. In table 4, all instances of "Cys-15Thr" should have been "–15 c/t"; "T460C" should have been "Cys154Arg"; "Gly2299Thr, Gly2814Thr" should have been "2299 g/t, 2814 g/t"; "Thr-8Cys" should have been "–8 c/t"; "Ala1401Gly, Ala1484Thr" should have been "1401 a/g, 1484 a/t"; "rrs Cys1402Thr" should have been "1402 c/t"; "eis Cys-14Thr" should have been "–14 c/t"; "Ala514Cys, Ala514Thr, Cys462Thr, Cys513Thr, Cys517Thr" should have been "514 a/c, 514 a/t, 462 c/t, 513 c/t, 517 c/t"; "Cys-8Thr, Cys-12Thr, Cys-16Thr" should have been "–8 c/t, –12 c/t, –16 c/t"; and "Gly-12Ala"

should have been "–12 g/a". The first sentence of the fifth paragraph of the "Relationship between results of genotypic and phenotypic drug resistance testing and clinical outcomes" section should have read "For rifampicin, more than 20 mutations in *rpoB* could have a negative effect on first-line treatment outcome, such as the Ile491Phe mutation found in Eswatini." The first sentence of the eighth paragraph of the same section should have read "For linezolid, *rrl* mutations 2814 g/t and 2270 g/t, and *rplC* mutation Cys154Arg are associated with treatment failure." The first sentence of the tenth paragraph of the same section should have read "For injectables such as amikacin, kanamycin, and capreomycin, the most commonly detected mutations are *rrs* 1401 a/g, 1402 c/t, 1484 a/t, and *eis* –14 c/t." These corrections have been made to the online version as of March 28, 2023.



Published Online
March 29, 2023
[https://doi.org/10.1016/S1473-3099\(23\)00196-2](https://doi.org/10.1016/S1473-3099(23)00196-2)



Published Online
March 28, 2023
[https://doi.org/10.1016/S1473-3099\(23\)00195-0](https://doi.org/10.1016/S1473-3099(23)00195-0)